Compare WEYS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEYS | PLX |
|---|---|---|
| Founded | 1906 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.9M | 230.0M |
| IPO Year | 1995 | 1996 |
| Metric | WEYS | PLX |
|---|---|---|
| Price | $31.86 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 4.7K | ★ 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $290,290,000.00 | $53,399,000.00 |
| Revenue This Year | N/A | $9.67 |
| Revenue Next Year | N/A | $23.86 |
| P/E Ratio | $21.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.51 | $1.34 |
| 52 Week High | $34.63 | $3.19 |
| Indicator | WEYS | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 55.89 |
| Support Level | $31.06 | $1.39 |
| Resistance Level | $33.40 | $3.03 |
| Average True Range (ATR) | 0.81 | 0.15 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 74.19 | 30.12 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.